Medison Pharma

Privately held: no public share price · Israel

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
fostamatinib(Tavalisse)
Approved
Spleen tyrosine kinase (Syk)Small molecule
Immune Thrombocytopenia

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

No financial reports recorded.